Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Whitlock

Showing results (261-270 of 272) with videos related to

Pageof 28
Sort By:
Pediatric Blood & Cancer|August 22, 2022
Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR)James A Whitlock, Jemily Malvar, Luciano Dalla-Pozza, et al.
Journal of Medicinal Chemistry|June 1, 2014
Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT₂C) receptor agonists with exquisite functional selectivity over 5-HT₂A and 5-HT₂B receptorsR Ian Storer, Paul E Brennan, Alan D Brown, et al.
Pediatric Blood & Cancer|February 4, 2010
Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conferenceTerzah M Horton, Richard Sposto, Patrick Brown, et al.
Lancet Regional Health. Americas|September 20, 2023
Developing a partnership to improve health care delivery to children <18 years with cancer and blood disorders in the English-speaking Caribbean: lessons from the SickKids-Caribbean Initiative (SCI)Michelle Reece-Mills, Curt Bodkyn, Jo-Anna B Baxter, et al.
Bioorganic & Medicinal Chemistry Letters|January 4, 2011
Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinenceMark D Andrews, Paul V Fish, Julian Blagg, et al.
Leukemia|May 6, 2018
Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma studyWeili Sun, Jemily Malvar, Richard Sposto, et al.
Blood|November 14, 2013
Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study groupTrudy D Buitenkamp, Shai Izraeli, Martin Zimmermann, et al.
Nature Cancer|December 30, 2022
The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutationsAnita Villani, Scott Davidson, Nisha Kanwar, et al.
JAMA Oncology|October 7, 2021
Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition SyndromesCatherine Goudie, Leora Witkowski, Noelle Cullinan, et al.
The New England Journal of Medicine|September 11, 2014
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemiaKathryn G Roberts, Yongjin Li, Debbie Payne-Turner, et al.
Pageof 28

Showing results (261-270 of 272) with videos related to

Sort By:
Pageof 28
Pediatric Blood & Cancer|August 22, 2022
Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR)James A Whitlock, Jemily Malvar, Luciano Dalla-Pozza, et al.
Journal of Medicinal Chemistry|June 1, 2014
Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT₂C) receptor agonists with exquisite functional selectivity over 5-HT₂A and 5-HT₂B receptorsR Ian Storer, Paul E Brennan, Alan D Brown, et al.
Pediatric Blood & Cancer|February 4, 2010
Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conferenceTerzah M Horton, Richard Sposto, Patrick Brown, et al.
Lancet Regional Health. Americas|September 20, 2023
Developing a partnership to improve health care delivery to children <18 years with cancer and blood disorders in the English-speaking Caribbean: lessons from the SickKids-Caribbean Initiative (SCI)Michelle Reece-Mills, Curt Bodkyn, Jo-Anna B Baxter, et al.
Bioorganic & Medicinal Chemistry Letters|January 4, 2011
Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinenceMark D Andrews, Paul V Fish, Julian Blagg, et al.
Leukemia|May 6, 2018
Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma studyWeili Sun, Jemily Malvar, Richard Sposto, et al.
Blood|November 14, 2013
Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study groupTrudy D Buitenkamp, Shai Izraeli, Martin Zimmermann, et al.
Nature Cancer|December 30, 2022
The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutationsAnita Villani, Scott Davidson, Nisha Kanwar, et al.
JAMA Oncology|October 7, 2021
Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition SyndromesCatherine Goudie, Leora Witkowski, Noelle Cullinan, et al.
The New England Journal of Medicine|September 11, 2014
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemiaKathryn G Roberts, Yongjin Li, Debbie Payne-Turner, et al.
Pageof 28